Entity

Time filter

Source Type

LJUBLJANA, Slovenia

Grant
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP.2011.1.2-2 | Award Amount: 11.03M | Year: 2012

The objective of the ALEXANDER project is the identification of novel strategies (e.g., proteolytic enzyme strategy, thiomer strategy, zeta potential changing systems, SNEDDS strategy) and the optimization of existing strategies (e.g., disulfide breaking strategy and slippery surface strategy) for the efficient transport of nanocarriers through the mucus gel layer (e.g., intestinal, nasal, ocular, vaginal, buccal, pulmonary). In particular, R&D activities will be focused on the synthesis of functionalized nanocarriers capable of permeating the mucus gel layer and delivering their therapeutic payload to the epithelium. The nanocarriers will be characterized with respect to their physicochemical properties, ability to cross the mucus gel layer, in vitro and in vivo cytotoxicity. The potential of the developed nanocarriers as delivery systems for mucosal administration of macromolecules will be demonstrated via the oral delivery of peptides, oligosaccharides and oligonucleotides and the nasal delivery of a plasmid encoding for an antigen.


Lek

Trademark
Lek Farmacevtska Druzba D.D. and Lek | Date: 1997-12-23

pharmaceutical preparations, namely, preparations for the treatment of the digestive tract and metabolism, preparations for the treatment of blood and blood producing organs, preparations for the treatment of the cardiovascular system, preparations for the treatment of the genitourinary system and sex hormones, systemic hormonal preparations, preparations for the treatment of musculo-skeletal system, preparations for the treatment of the central nervous system, preparations for the treatment of parasitizations, preparations for the treatment of the respiratory system and sense organs, general systemic anti-infectives, dialysis solutions, and cytostatics; dermatological preparations, namely, creams, ointments, gels, sprays and solutions, all for use in dermatology and all for external use; veterinary preparations for the treatment of a variety of illnesses and conditions in domestic animals and livestock; dietary food supplements adapted for medical use; dietary food supplements for babies; medical plaster; surgical dressings; dental polish; dental impression materials; dental amalgams, cements and mastics; general purpose disinfectants; exterminating preparations, namely, vermin poison; fungicides; and herbicides.


Grant
Agency: Cordis | Branch: H2020 | Program: IA | Phase: BIOTEC-4-2014 | Award Amount: 10.57M | Year: 2015

The scope of the project is the optimization of downstream process (DSP) for the production of Biopharmaceuticals. Biopharmaceuticals have been successfully used as efficient therapeutic drugs for many pathophysiological conditions since the first recombinant product, insulin, was approved in 1982. Despite its efficacy, accessibility is still limited due to extremely high costs. In the production chain, capturing and purifying still represents a major bottleneck. Consequently, improvements in this area produce substantial cost reductions and expand patients accessibility to highly efficient drugs. Another aim of this action is to cope with the changing manufacturing demands, by lowering its environmental footprint and moving to more sustainable technologies. This proposals main objective is to implement a fully integrated manufacturing platform based on continuous chromatography in combination with disposable techniques for all unit operations of the DSP sequence for biosimilar monoclonal antibodies and derivatives thereof. The action encompasses the entire DSP sequence. We will implement alternative technologies for primary separation, such as flocculation or tangential flow filtration. The expected outcome is a reduction in the size and number of downstream unit operations and the elimination of centrifugation. Alternative approaches to the batch process for the capture step, such as continuous chromatography, will be evaluated in order to improve the efficiency and lower the need for expensive resin volume. Additionally precipitation utilization will be evaluated as an approach to replace protein A chromatography as capture step. A disposable continuous chromatography system will be developed together with novel analytical tools and sensors. Since single-use disposable systems can substitute the extensive use of resources (water) and significantly reduce the overall utility needs, the whole DSP sequence will be carried out on disposable technology (PAT).

Discover hidden collaborations